Kidney Health Initiative (KHI)

KHI Mission

Kidney Health Initiative

To advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.

KHI to Hold Public Workshop on Roadmap for Innovative RRT Alternatives in 2017

In June, KHI members and leadership participated in the White House Organ Summit, reflecting KHI's commitment to enhancing patient safety and fostering innovation in kidney disease. The Summit examined ways to improve the outcomes for individuals waiting for organ transplants and support living donors in addition to improving kidney patient care options and transplantation access.

As part of its broader commitment made during the White House Organ Summit, KHI will host a public workshop for entrepreneurs and developers in the first quarter of 2017, with involvement from the U.S. Food and Drug Administration, the National Institutes of Health (NIH) and the Centers for Medicare & Medicaid Services (CMS), to discuss the scientific, technical, and regulatory roadmap to create a bioartificial or bioengineered alternative to dialysis.

Please view the Development of a Roadmap for Innovations in Renal Replacement Therapy (RRT) project page for more information on KHI's efforts to draft a Roadmap. The KHI website will continue to be updated as information becomes available.

If you have any questions or are interested in this workshop and joining a mailing list, please email

KHI Annual Report 2015-2016

On behalf of the Board of Directors, we would like to thank the KHI membership for their participation in KHI, which has seen its membership grow from 47 organizations in September 2013, to more than 75 organizations in December 2015. The membership has worked diligently through KHI to improve patient safety and promote the development of optimal therapies for diseases that affect kidneys and the quality of life for millions of people.

View KHI's 2015-2016 Annual Report.

View KHI's 2014-2015 Annual Report.

View the KHI Inaugural Review 2012-2014.

Fifth Annual KHI Stakeholders Meeting

The Fifth Annual KHI Stakeholders Meeting will take place in the Washington, DC area on May 24-25, 2017. The Stakeholders Meeting will bring together our diverse membership from the kidney community to connect members across different fields, share ideas, collect feedback, and collaborate on new and proposed projects.

Please continue to check the KHI website for more information and visit the KHI Meetings Page for information on past meetings.

KHI Announces New Members of the KHI Board of Directors

KHI thanks the Nominating Committee for preparing the 2016 Call for Nominations and slate. The KHI Board of Directors welcomes new members David Baron, PhD, and Marcus Ketteler, MD, to the Board starting in January 2017.

Additionally, a special thanks to members who completed their term in 2016 – Patrick Archdeacon, MD, Dolph Chianchano, JD, MPA, and Alan Kliger, MD. In particular, we would like to acknowledge Founding Co-Chair, Patrick Archdeacon, MD, for his leadership and guidance, which were instrumental in establishing KHI.

For a more detailed update on KHI Board of Directors, please click here.

Open Call for Workgroups

The following is a list of current opportunities for KHI members to volunteer their service on a project workgroup. Click on the title for more information and details on how to volunteer.

Involvement in workgroups is on a voluntary basis with no compensation provided. All workgroup members are required to submit an online disclosure form with their application.

KHI Publications

Learn More

If you have any questions about KHI, or would like more information about becoming a member, please contact